为药物安全和药物监督利用生成性人工智能
Hara Prasad Mishra1, Rachna Gupta1
1Department of Pharmacology, University College of Medical Sciences, University of Delhi, Delhi, India.
Current reviews in clinical and experimental pharmacology
|September 6, 2024
概括
生成型人工智能 (AI) 通过改善不良事件检测和风险预测来增强药物监测和药物安全监测. 需要进一步的研究才能充分了解其对安全分析质量的影响.
科学领域:
- 药监和药物安全 药监和药物安全
- 医疗保健中的人工智能
背景情况:
- 人工智能 (AI),特别是机器学习,越来越多地用于预测.
- 生成型人工智能对制药开发和市场监督越来越感兴趣.
- 药物监测依赖于在开发阶段和市场后阶段监测药物安全.
研究的目的:
- 审查生成AI在药物监测和药物安全监测中的作用.
- 了解生成AI在评估药品安全方面的潜在好处和应用.
主要方法:
- 系统审查已发表的文章和新闻项目.
- 在PubMed和Google Scholar上使用关键词进行的搜索:药物监测,人工智能,机器学习,药物安全,患者安全.
- 分析到2024年1月31日发表的109篇文章.
主要成果:
- 生成型人工智能在药物监测中提供了变革性的潜力,增强了不良事件的检测和风险预测.
- 人工智能和自动化简化了安全数据分析,在各种疾病状态中处理大型数据集.
- 应用包括优化药物开发和改善与安全相关数据的评估.
结论:
- 生成型人工智能显著有利于药物监测和药物安全监测.
- 预计人工智能将越来越多地用于预测副作用和不良药物反应 (ADR).
- 需要进一步调查以确定人工智能驱动的优化对安全分析质量的影响.
更多相关视频
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
4.1K
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
2.8K
相关概念视频
Pharmacovigilance
789
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
789
Drug Discovery: Overview
7.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.7K
Structure-Activity Relationships and Drug Design
679
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
679
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Drug Control Governance: Regulatory Bodies and Their Impact
146
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
146
Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
